#USA #Securities Fraud #Bensalem #Howard G. Smith #Regeneron Pharmaceuticals

Recent Developments in Regeneron Pharmaceuticals' Securities Fraud Lawsuit

Investors who sustained significant losses in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) now have a critical opportunity to spearhead a class action lawsuit regarding alleged securities fraud. According to the Law Offices of Howard G. Smith, which announced this development, investors have until March 10, 2025, to step forward and assume a leadership role in the ongoing litigation.

Background of the Lawsuit

The lawsuit centers on a complaint filed against Regeneron that spans the period from November 2, 2023, to October 30, 2024. Allegations claim that the company misleadingly reported its financial condition by failing to disclose various critical facts, significantly impacting investor decision-making. Key accusations include:

1. Undisclosed Payments: Regeneron purportedly paid credit card fees to distributors contingent upon those distributors not charging higher prices to customers using credit cards for Eylea, a prominent treatment developed by the company.
2. Price Subsidization: These payments allegedly subsidized the prices clients paid when utilizing credit cards to purchase Eylea, contradicting previously communicated pricing policies.
3. Inflated Sales Figures: As a consequence, Regeneron reportedly provided misleadingly optimistic sales figures for Eylea, exposing potential investors to inflated expectations that did not align with the true market conditions.
4. False Financial Statements: Furthermore, by not declaring these payments as price concessions, Regeneron might have overstated the Average Selling Price (ASP) reported to federal authorities, leading to possible violations of the False Claims Act.

The ramifications of these actions suggest that Regeneron's optimistic outlook communicated to investors during this timeframe was not based on a sound foundation, causing significant financial repercussions for those invested in the company.

Who Can Participate?

The Law Offices of Howard G. Smith is actively encouraging investors who suffered losses in Regeneron stocks to participate in the class action. Potential lead plaintiffs must act before the March 10 deadline to ensure they have the opportunity to represent their fellow investors. Participation does not necessarily require immediate legal counsel; investors can choose to remain passive members of the class action if they prefer.

Next Steps for Affected Investors

Those interested in leading or participating in the class action against Regeneron can take the following steps:

• - Contact Legal Counsel: Reach out to the Law Offices of Howard G. Smith via email at [email protected] or call (215) 638-4847 for further information and assistance regarding your rights as an investor.
• - Stay Informed: Investors are encouraged to stay updated on developments related to this case and how it may unfold, as well as potential compensatory settlements that may result from the lawsuit.

Conclusion

With the March 10 deadline approaching, affected investors must act swiftly to either lead or join this critical class action lawsuit against Regeneron Pharmaceuticals. The outcome could have significant financial implications for those involved, potentially offering a pathway to reclaim some of their losses attributed to the alleged wrongdoing of the company. Investors are reminded to consult legal experts to understand their rights and options fully.

For more detailed information about the ongoing litigation or to learn more about the necessary actions to take, visit the Law Offices of Howard G. Smith's website or reach out directly for personalized legal advice.